Chlorproguanil/dapsone

Chlorproguanil/dapsone
Combination of
Chlorproguanil	Antimalarial drug
Dapsone	Antibiotic
Legal status
Legal status	Withdrawn;
Identifiers
CAS Number	209665-78-1;

Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,[1] which act synergystically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.[2]

References

Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". The Lancet. Infectious Diseases. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.
Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264. S2CID 34866078.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid12614733-1] Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". The Lancet. Infectious Diseases. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.

[pmid20599264-2] Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264. S2CID 34866078.